Consumer healthcare solutions

N-nitrosodimethylamine (NDMA) is reported to be a probable human carcinogen and is related to the widespread recalls of the blood pressure and heart medications losartan, valsartan and irbesartan. It is believed that these drugs were contaminated with cancer related impurities through manufacturing processes at pharmaceutical ingredient plants.

A recent FDA statement about NDMA impurities is that levels have been detected in ranitidine medicines. The FDA is reported to have requested that ranitidine manufacturers conduct laboratory testing to examine levels of NDMA in ranitidine.  

The EMA is reported to have initiated a review of ranitidine medicines after tests showed that some products contained NDMA.

----------------------------------------------------------------------------------------

With cGMP labs in the UK, Germany and US we provide contract analytical research and testing services, consultancy and quality control solutions to support Chemistry, Manufacturing and Control (CMC) requirements at all stages of your product pipeline from development to commercial manufacture.

Our expert knowledge covers a wide range of consumer products including creams, ointments, toothpaste, shampoos, OINDPs, pMDIs.

Our comprehensive service offering covers both chemical analyses, including assay, impurity and identification, as well as physicochemical properties. Our expertise covers characterisation, stability and release testing across raw materials, excipients, actives and formulated products.